Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Insights > Key Points and Accurate Workflow for Rapid Release Testing
Key Points and Accurate Workflow for Rapid Release Testing
Release time: 2025-06-13 Source: ACROBiosystems Read: 323

Key Points and Accurate Workflow for Rapid Release Testing

Comprehensive Mycoplasma Detection Solutions Empower Rapid Product Release for Biologics!

Click to learn more

In the biopharmaceutical field, mycoplasma contamination acts like an invisible killer, constantly threatening drug safety and patient health. As the industry evolves rapidly, mycoplasma testing methods are no longer sufficient to meet the timeliness requirements of modern drug production. The emergence of rapid release testing technologies has opened a new door for the biopharmaceutical industry—one that is both safe and highly efficient. This technology not only significantly shortens the detection cycle but also provides a powerful safeguard for biologics quality control.

1. Mycoplasma Detection: The Safety Cornerstone of Biopharmaceuticals

(1). Hazards of Mycoplasma

As the smallest self-replicating prokaryotes, mycoplasmas can cause abnormal cell growth, metabolic disruption, or even apoptosis, thereby endangering patient health. For instance, Mycoplasma pneumoniae infection often leads to pneumonia with symptoms such as persistent fever, dry cough, and chest pain, which may escalate to respiratory distress and complications. In manufacturing, mycoplasma contamination may stem from raw materials, personnel, or the lab environment, and poses hidden, persistent risks—necessitating strict monitoring at every stage of the production process.

(2). Limitations of Detection Methods

Culture-based detection methods take 28 days to yield results, severely limiting product release speed. While PCR has reduced testing time, it still carries risks of false positives/negatives and does not fully meet the demands for rapid and accurate modern drug testing.

2. Rapid Release Testing: An Innovative Solution for Mycoplasma Detection

By integrating advanced technologies such as nucleic acid amplification and fluorescence detection, rapid release testing achieves highly sensitive detection of mycoplasma DNA. This method shortens testing cycles to just hours while maintaining precision and reliability. It detects ultra-low levels of contamination and provides a solid basis for quality assessment.

The adoption of rapid testing has shortened biologics release times from weeks to days, significantly boosting manufacturing efficiency and reducing batch failure risks—saving companies substantial costs. In the age of precision medicine, this technology plays a vital role in emerging areas like cell and gene therapy. Its continued innovation is propelling the biopharma QC framework to new heights, ensuring safer and more effective treatments for patients.

3. Accurate Workflow: ACROBiosystems Supports Robust Quality Control

(1). Sample Preparation

Sample preparation is critical in rapid release testing. Optimized lysis buffers and nucleic acid extraction solutions maximize DNA recovery while removing PCR inhibitors. The use of automated nucleic acid extraction instruments is especially recommended, as it further enhances the consistency and reliability of sample processing.

(2). Standardization of Detection Methods

Standardization ensures accuracy. Validated primer-probe combinations and optimized reaction systems minimize inter-batch variability. Real-time qPCR allows real-time monitoring, enhancing accuracy and reproducibility.

ACROBiosystems’ Mycoplasma DNA Sample Preparation Kit (Cat. No. OPA-E101) and Mycoplasma Detection Kits (Cat. No. OPA-S102) comply with pharmacopoeial testing requirements in multiple regions, including China, the U.S., and Europe. They are supported by third-party validation reports from Eurofins. The qPCR detection performance is consistent with culture methods and indicator cell assays, covering all strains required by the aforementioned pharmacopeias. In addition, human mycoplasma has been specifically validated, providing more comprehensive scientific evidence for detection efficacy.

Key Points and Accurate Workflow for Rapid Release Testing

ACROBiosystems offers a comprehensive mycoplasma detection solution.

Click to learn more

(3). Full-Process QC Optimization & Support

Establishing a QC system involves staff training, equipment calibration, and reagent validation. standard operating procedures (SOPs) and strict process control ensure traceability. ACROBiosystems’ technical team supports platform setup, workflow optimization, validation planning, and regulatory submissions—saving time and cost through turnkey solutions.

Click to Inquire

Validation Data

• Broad Coverage: Detects over 250 species of Mycoplasma and Mollicutes.

Number of Mollicutes detected with a Database match
GenusNo.
    Mycoplasma    >200
    Acholeplasma    14
    Spiroplasma    25
    Ureaplasma    7

• High Sensitivity: Meets regulatory standards (10 CFU/mL).

IDMycoplasma SpeciesCompendia requirements (CFU/mL)ResultsLimit (CFU/mL)
1     Mycoplasma orale    1024/241
2     Mycoplasma pneumoniae    1024/240.1
3     Mycoplasma hyorhinis    1024/241
4     Mycoplasma salivarium    1024/241
5     Mycoplasma fermentans    1024/241
6     Mycoplasma synoviae    1024/241
7     Mycoplasma gallisepticum    1024/241
8     Mycoplasma arginini    1024/241
9     Acholeplasma laidlawii    1024/240.1
10     Spiroplasma citri    1024/240.1

Tested 10 mycoplasma standards (10 CFU/mL) in 24 replicates each; all returned positive—meeting/exceeding EP 2.6.7 standards (10 CFU/mL).

• High Specificity: No cross-reactivity.

Unrelated strain/Cell lineCt ValueResult
    Streptococcus pneumoniae    UndeterminedUndetermined0/2
    Lactobacillus acidophilus    UndeterminedUndetermined0/2
    Staphylococcus epidermidis    UndeterminedUndetermined0/2
    Clostridium sporogenes    UndeterminedUndetermined0/2
    Clostridium acetobutylicum    UndeterminedUndetermined0/2
CHO(106 cells/mL)UndeterminedUndetermined0/2
HEK293(106 cells/mL)UndeterminedUndetermined0/2
T cell(107 cells/mL)UndeterminedUndetermined0/2
Pichia pastoris UndeterminedUndetermined0/2
E.coliUndeterminedUndetermined0/2

Tested against two cell lines and four unrelated bacteria (e.g., Streptococcus pneumoniae, Lactobacillus acidophilus, Staphylococcus epidermidis, Bacillus subtilis)—all negative, confirming no cross-reactivity.

Click to Inquire

Additional Product Recommendations

• Recombinant Factor C Endotoxin Detection Kit

• SAFENSURE™ Advanced Safety Testing Solution for Biologics

• Rapid BSA Residue Detection Kit

• Cas9 Residue Detection Kit

• Host Cell DNA Residual Detection Kit

• resDetect™ CMC Process Residual Detection Solutions

A Comprehensive Guide to Sample Dilution Calculations for Recombinant Factor C Endotoxin Testing

>>>Click to learn more about our new brand—SAFENSURE™

Upcoming Mycoplasma Detection Insights Series !

Part 1: Mycoplasma Detection: A Critical Defense for Ensuring Biopharmaceutical Quality

Part 2: Unlocking Biologic Safety: Key Points and Accurate Workflow for Rapid Release Testing

Part 3: Accelerating Cell Culture and Product Release: High-Efficiency Methods

Part 4: Overcoming Detection Challenges: From Traditional to Rapid Testing

Part 5: Ensuring Sample Purity: Case Studies & Best Practices

Part 6: Entering the Era of Precision Detection: Innovations and Applications

Part 7: Regulatory Excellence: Compliance & Industry Standards for Rapid Testing

References

1. U.S. Food and Drug Administration. (2018). Elimination of 21 CFR 610.30 Test for Mycoplasma. Federal Register.

2. Marians, R. C., Brenton, M., LaBombard, S., et al. (2014). Regulatory Aspects of Mycoplasma Testing for Cell Therapy Products. LABS, Inc.

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message